Syringeable atorvastatin loaded eugenol enriched PEGylated cubosomes in-situ gel for the intra-pocket treatment of periodontitis: statistical optimization and clinical assessment
AbstractAtorvastatin calcium (ATV) is a well-known anti-hyperlipidemic drug currently being recognized for possessing an anti-inflammatory effect. Introducing it as a novel remedy for periodontitis treatment necessitates developing a syringeable modified delivery system capable of targeting inflamma...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-12-01
|
Series: | Drug Delivery |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/10717544.2022.2162159 |
_version_ | 1797260937573433344 |
---|---|
author | Heba Amin Elgendy Amna M. A. Makky Yara E. Elakkad Radwa M. Ismail Nihal Farid Younes |
author_facet | Heba Amin Elgendy Amna M. A. Makky Yara E. Elakkad Radwa M. Ismail Nihal Farid Younes |
author_sort | Heba Amin Elgendy |
collection | DOAJ |
description | AbstractAtorvastatin calcium (ATV) is a well-known anti-hyperlipidemic drug currently being recognized for possessing an anti-inflammatory effect. Introducing it as a novel remedy for periodontitis treatment necessitates developing a syringeable modified delivery system capable of targeting inflammation within the periodontal pockets. Thus, a 33 Box-Behnken design was used to generate eugenol enriched PEGylated cubosomes. Based on the desirability function, the optimized formulation (OEEPC) was selected exhibiting a solubilization efficiency (SE%) of 97.71 ± 0.49%, particle size (PS) of 135.20 ± 1.11 nm, polydispersity index (PDI) of 0.09 ± 0.006, zeta potential (ZP) of −28.30 ± 1.84 mV and showing a sustained drug release over 12 h. It displayed a cubic structure under the transmission electron microscope, furthermore, it was stable upon storage for up to 30 days. Hence, it was loaded into an optimum syringeable in-situ gel (ISG) which displayed the desired periodontal gelation temperature (34 ± 0.70 °C) and an adequate gelation time (46 ± 2.82 sec), it also released approximately 75% of the drug within 72 h. Clinical evaluation of the ISG showed a promising percentage reduction of about 58.33% in probing depth, 90% in the bleeding index, 81.81% in the plaque index, and 70.21% in gingival levels of transforming growth factor–β1. This proved that the formulated syringeable intra-pocket delivery system of ATV is an efficient candidate for diminishing inflammation in periodontitis. |
first_indexed | 2024-03-08T23:31:35Z |
format | Article |
id | doaj.art-46c3387d917d49959bdb38b6efcd9502 |
institution | Directory Open Access Journal |
issn | 1071-7544 1521-0464 |
language | English |
last_indexed | 2024-04-24T23:33:16Z |
publishDate | 2023-12-01 |
publisher | Taylor & Francis Group |
record_format | Article |
series | Drug Delivery |
spelling | doaj.art-46c3387d917d49959bdb38b6efcd95022024-03-15T14:22:18ZengTaylor & Francis GroupDrug Delivery1071-75441521-04642023-12-0130110.1080/10717544.2022.2162159Syringeable atorvastatin loaded eugenol enriched PEGylated cubosomes in-situ gel for the intra-pocket treatment of periodontitis: statistical optimization and clinical assessmentHeba Amin Elgendy0Amna M. A. Makky1Yara E. Elakkad2Radwa M. Ismail3Nihal Farid Younes4Department of Pharmaceutics, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology, Giza, EgyptDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, EgyptDepartment of Pharmaceutics, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology, Giza, EgyptDepartment of Oral Medicine, Periodontology and Oral Diagnosis, Faculty of Dentistry, Misr University for Science and Technology, Giza, EgyptDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, EgyptAbstractAtorvastatin calcium (ATV) is a well-known anti-hyperlipidemic drug currently being recognized for possessing an anti-inflammatory effect. Introducing it as a novel remedy for periodontitis treatment necessitates developing a syringeable modified delivery system capable of targeting inflammation within the periodontal pockets. Thus, a 33 Box-Behnken design was used to generate eugenol enriched PEGylated cubosomes. Based on the desirability function, the optimized formulation (OEEPC) was selected exhibiting a solubilization efficiency (SE%) of 97.71 ± 0.49%, particle size (PS) of 135.20 ± 1.11 nm, polydispersity index (PDI) of 0.09 ± 0.006, zeta potential (ZP) of −28.30 ± 1.84 mV and showing a sustained drug release over 12 h. It displayed a cubic structure under the transmission electron microscope, furthermore, it was stable upon storage for up to 30 days. Hence, it was loaded into an optimum syringeable in-situ gel (ISG) which displayed the desired periodontal gelation temperature (34 ± 0.70 °C) and an adequate gelation time (46 ± 2.82 sec), it also released approximately 75% of the drug within 72 h. Clinical evaluation of the ISG showed a promising percentage reduction of about 58.33% in probing depth, 90% in the bleeding index, 81.81% in the plaque index, and 70.21% in gingival levels of transforming growth factor–β1. This proved that the formulated syringeable intra-pocket delivery system of ATV is an efficient candidate for diminishing inflammation in periodontitis.https://www.tandfonline.com/doi/10.1080/10717544.2022.2162159Intra-pocket deliveryperiodontitisatorvastatincubosomesBox-Behnken designand clinical assessment |
spellingShingle | Heba Amin Elgendy Amna M. A. Makky Yara E. Elakkad Radwa M. Ismail Nihal Farid Younes Syringeable atorvastatin loaded eugenol enriched PEGylated cubosomes in-situ gel for the intra-pocket treatment of periodontitis: statistical optimization and clinical assessment Drug Delivery Intra-pocket delivery periodontitis atorvastatin cubosomes Box-Behnken design and clinical assessment |
title | Syringeable atorvastatin loaded eugenol enriched PEGylated cubosomes in-situ gel for the intra-pocket treatment of periodontitis: statistical optimization and clinical assessment |
title_full | Syringeable atorvastatin loaded eugenol enriched PEGylated cubosomes in-situ gel for the intra-pocket treatment of periodontitis: statistical optimization and clinical assessment |
title_fullStr | Syringeable atorvastatin loaded eugenol enriched PEGylated cubosomes in-situ gel for the intra-pocket treatment of periodontitis: statistical optimization and clinical assessment |
title_full_unstemmed | Syringeable atorvastatin loaded eugenol enriched PEGylated cubosomes in-situ gel for the intra-pocket treatment of periodontitis: statistical optimization and clinical assessment |
title_short | Syringeable atorvastatin loaded eugenol enriched PEGylated cubosomes in-situ gel for the intra-pocket treatment of periodontitis: statistical optimization and clinical assessment |
title_sort | syringeable atorvastatin loaded eugenol enriched pegylated cubosomes in situ gel for the intra pocket treatment of periodontitis statistical optimization and clinical assessment |
topic | Intra-pocket delivery periodontitis atorvastatin cubosomes Box-Behnken design and clinical assessment |
url | https://www.tandfonline.com/doi/10.1080/10717544.2022.2162159 |
work_keys_str_mv | AT hebaaminelgendy syringeableatorvastatinloadedeugenolenrichedpegylatedcubosomesinsitugelfortheintrapockettreatmentofperiodontitisstatisticaloptimizationandclinicalassessment AT amnamamakky syringeableatorvastatinloadedeugenolenrichedpegylatedcubosomesinsitugelfortheintrapockettreatmentofperiodontitisstatisticaloptimizationandclinicalassessment AT yaraeelakkad syringeableatorvastatinloadedeugenolenrichedpegylatedcubosomesinsitugelfortheintrapockettreatmentofperiodontitisstatisticaloptimizationandclinicalassessment AT radwamismail syringeableatorvastatinloadedeugenolenrichedpegylatedcubosomesinsitugelfortheintrapockettreatmentofperiodontitisstatisticaloptimizationandclinicalassessment AT nihalfaridyounes syringeableatorvastatinloadedeugenolenrichedpegylatedcubosomesinsitugelfortheintrapockettreatmentofperiodontitisstatisticaloptimizationandclinicalassessment |